Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company usually posts poor financials for mid or long term investments.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The group usually releases upbeat results with huge surprise rates.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • Low profitability weakens the company.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
POXEL46.17%213
GILEAD SCIENCES7.00%84 676
VERTEX PHARMACEUTICALS32.38%56 411
REGENERON PHARMACEUTICALS-2.11%39 972
WUXI APPTEC CO., LTD.69.25%20 952
GENMAB51.29%15 253
BEIGENE, LTD.30.15%11 160
NEUROCRINE BIOSCIENCES, INC..59.29%10 476
AMARIN CORPORATION PLC65.83%8 101
SAREPTA THERAPEUTICS, INC.-3.10%7 883
ARROWHEAD PHARMACEUTICALS, ..445.65%6 798
REATA PHARMACEUTICALS, INC.261.52%6 626
ARGENX SE61.27%6 499
HUALAN BIOLOGICAL ENGINEERI..--.--%6 476
PEPTIDREAM INC.20.75%5 901
-
EXELIXIS, INC.-14.44%5 114
More Results
Financials (EUR)
Sales 2019 35,0 M
EBIT 2019 -19,8 M
Net income 2019 -20,0 M
Finance 2019 25,3 M
Yield 2019 -
P/E ratio 2019 -9,50x
P/E ratio 2020 -5,33x
EV / Sales2019 4,77x
EV / Sales2020 7,26x
Capitalization 192 M
Upcoming event on POXEL
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes